Braf v600e and rnf43 co-mutations predict patient outcomes with targeted therapies in real-world cases of colorectal cancer

HIGHLIGHTS

• who: BRAF and colleagues from the Elez et al, recently showed the novel potential of , mutations to predict clinical benefit and favorable outcomes in patients with metastatic microsatellite stable (MSS) colorectal cancer (mCRC) and BRAFV E mutated treated with antiEGFR/BRAF combinatory regimensMotivated by the potential of these findings for optimizing the clinical management of mCRC, we sought to leverage the established Flatiron HealthFoundation Medicine (FH-FMI) real-world clinico-genomic database (CGDB) to independently and rapidly validate these findings to help accelerate biomarker development. As described by Elez et al [1] BRAFV E mutations are present . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.